サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1654422

先端巨大症治療の市場規模、シェア、動向分析レポート：薬剤クラス別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

Acromegaly Treatment Market Size, Share & Trends Analysis Report By Drug Class (Somatostatin Analogs, GHRA, Dopamine Agonists), By Distribution Channel (Hospitals & Clinics), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
先端巨大症治療の市場規模、シェア、動向分析レポート：薬剤クラス別、流通チャネル別、地域別、セグメント別予測、2025年～2030年
出版日: 2025年01月28日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

先端巨大症治療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の先端巨大症治療市場規模は、2025～2030年にかけて6.4%のCAGRを記録し、2030年までに23億7,000万米ドルに達すると推定されています。

先端巨大症の罹患率の増加が成長を促進すると予想されています。例えば、内分泌学会の報告書によると、2015年の疾患有病率は前年の2014年から4倍に増加しました。さらに、さまざまな製薬会社が新しい分子を開発するために臨床検査への投資を拡大していることも、市場の成長を後押しする要因となっています。

さらに、薬剤の強力なパイプラインは、今後数年間で成長機会を生み出すと予想されています。例えば、Chiasma Inc.のMycapssaは2016年に欧州で承認を取得しました。2018年には、Antisense Therapeuticsが米国で新製剤ALT1103を発売しました。成長ホルモン受容体拮抗薬であるIonis Pharmaceuticals Inc.のISIS 766720は現在第II相臨床検査中であり、2019年12月までに終了する見込みです。

ソマトスタチン類似体の強力なパイプラインは、近い将来、先端巨大症治療市場の成長を促進すると予想されます。例えば、2018年には北米で約30件の臨床検査が実施され、多くが米国食品医薬品局（FDA）の承認を待っています。

先端巨大症治療市場レポートハイライト

  • 薬剤クラス別では、ソマトスタチン類似体（SSA）セグメントが2024年に65.0％の最大市場シェアを獲得しました。
  • 流通チャネル別では、病院薬局セグメントが2024年に49.8%の最大シェアを獲得しました。
  • 北米は2024年に38.7％の最大売上シェアを記録したが、これは同地域の先進的医療インフラ、高い認知度、最先端治療へのアクセスによるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 先端巨大症治療市場の変数、動向、範囲

  • 市場系統の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 産業分析-ポーターのファイブフォース分析
    • PESTLE分析

第4章 先端巨大症治療市場：薬剤クラスビジネス分析

  • 薬剤クラス市場シェア、2024年と2030年
  • 薬剤クラスセグメントダッシュボード
  • 市場規模と予測と動向分析、薬剤クラス別、2018～2030年
  • ソマトスタチン類似体（SSA）
  • 成長ホルモン受容体拮抗薬（GHRA）
  • ドーパミン作動薬
  • その他

第5章 先端巨大症治療市場：流通チャネルビジネス分析

  • 流通チャネル市場シェア、2024年と2030年
  • 流通チャネルセグメントダッシュボード
  • 市場規模と予測と動向分析、流通チャネル別、2018～2030年
  • 病院薬局
  • 小売薬局
  • その他

第6章 先端巨大症治療市場：地域別、推定・動向分析

  • 地域別市場シェア分析、2024年と2030年
  • 地域別市場ダッシュボード
  • 市場規模、予測動向分析、2018～2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • ノルウェー
    • スウェーデン
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Novartis AG
    • Ipsen Pharma
    • Sun Pharmaceutical Industries Ltd
    • Chiasma, Inc.
    • Peptron, Inc.
    • WOCKHARDT
    • Dauntless Pharmaceuticals
    • Pfizer Inc.
    • Ionis Pharmaceuticals, Inc.
図表

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Acromegaly Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 4. Global Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 5. Global Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 6. North America Acromegaly Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 7. North America Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 8. North America Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 9. U.S. Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 10. U.S. Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11. Canada Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 12. Canada Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13. Mexico Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 14. Mexico Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15. Europe Acromegaly Treatment market, by country, 2018 - 2030 (USD Million)
  • Table 16. Europe Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 17. Europe Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 18. UK Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 19. UK Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20. Germany Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 21. Germany Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 22. France Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 23. France Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24. Italy Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 25. Italy Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26. Spain Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 27. Spain Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28. Denmark Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 29. Denmark Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30. Norway Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 31. Norway Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32. Sweden Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 33. Sweden Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34. Asia Pacific Acromegaly Treatment market, by country, 2018 - 2030 (USD Million)
  • Table 35. Asia Pacific Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 36. Asia Pacific Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37. Japan Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 38. Japan Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39. China Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 40. China Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41. India Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 42. India Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43. South Korea Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 44. South Korea Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 45. Australia Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 46. Australia Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47. Thailand Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 48. Thailand Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49. Latin America Acromegaly Treatment market, by country, 2018 - 2030 (USD Million)
  • Table 50. Latin America Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 51. Latin America Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52. Brazil Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 53. Brazil Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54. Argentina Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 55. Argentina Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56. Middle East & Africa Acromegaly Treatment market, by country, 2018 - 2030 (USD Million)
  • Table 57. Middle East & Africa Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 58. Middle East & Africa Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59. South Africa Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 60. South Africa Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61. Saudi Arabia Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 62. Saudi Arabia Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63. UAE Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 64. UAE Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65. Kuwait Acromegaly Treatment Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 66. Kuwait Acromegaly Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Acromegaly Treatment Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Data Triangulation Techniques
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Snapshot
  • Fig. 9 Drug Class and Distribution Channel Outlook (USD Million)
  • Fig. 10 Competitive Landscape
  • Fig. 11 Acromegaly Treatment Market Dynamics
  • Fig. 12 Acromegaly Treatment Market: Porter's Five Forces analysis
  • Fig. 13 Acromegaly Treatment Market: PESTLE Analysis
  • Fig. 14 Acromegaly Treatment Market: Drug Class Segment Dashboard
  • Fig. 15 Acromegaly Treatment Market: Drug Class Market Share Analysis, 2024 & 2030
  • Fig. 16 Somatostatin Analogues (SSAs) Market, 2018 - 2030 (USD Million)
  • Fig. 17 Growth Hormone Receptor Antagonists (GHRAs) Market, 2018 - 2030 (USD Million)
  • Fig. 18 Dopamine Agonists Market, 2018 - 2030 (USD Million)
  • Fig. 19 Others Market, 2018 - 2030 (USD Million)
  • Fig. 20 Acromegaly Treatment Market: Distribution Channel Segment Dashboard
  • Fig. 21 Acromegaly Treatment Market: Distribution Channel Market Share Analysis, 2024 & 2030
  • Fig. 22 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 23 Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 24 Others Market, 2018 - 2030 (USD Million)
  • Fig. 25 Acromegaly Treatment Market Revenue, By Region
  • Fig. 26 Regional Marketplace: Key Takeaways
  • Fig. 27 Regional Marketplace: Key Takeaways
  • Fig. 28 North America Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. Country Dynamics
  • Fig. 30 U.S. Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada Country Dynamics
  • Fig. 32 Canada Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 33 Mexico Country Dynamics
  • Fig. 34 Mexico Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 35 Europe Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 36 UK Country Dynamics
  • Fig. 37 UK Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 38 Germany Country Dynamics
  • Fig. 39 Germany Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 40 France Country Dynamics
  • Fig. 41 France Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy Country Dynamics
  • Fig. 43 Italy Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 44 Spain Country Dynamics
  • Fig. 45 Spain Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 46 Denmark Country Dynamics
  • Fig. 47 Denmark Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 48 Norway Country Dynamics
  • Fig. 49 Norway Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 50 Sweden Country Dynamics
  • Fig. 51 Sweden Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 53 Japan Country Dynamics
  • Fig. 54 Japan Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 55 China Country Dynamics
  • Fig. 56 China Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 57 India Country Dynamics
  • Fig. 58 India Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 59 South Korea Country Dynamics
  • Fig. 60 South Korea Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 61 Australia Country Dynamics
  • Fig. 62 Australia Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 63 Thailand Country Dynamics
  • Fig. 64 Thailand Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 65 Latin America Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 66 Brazil Country Dynamics
  • Fig. 67 Brazil Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 68 Argentina Country Dynamics
  • Fig. 69 Argentina Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 70 MEA Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 71 South Africa Country Dynamics
  • Fig. 72 South Africa Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia Country Dynamics
  • Fig. 74 Saudi Arabia Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 75 UAE Country Dynamics
  • Fig. 76 UAE Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 77 Kuwait Key Country Dynamics
  • Fig. 78 Kuwait Acromegaly Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 79 Company Categorization
  • Fig. 80 Company Market Position Analysis
  • Fig. 81 Strategic Framework
目次
Product Code: GVR-3-68038-053-8

Acromegaly Treatment Market Growth & Trends:

The global acromegaly treatment market size is estimated to reach USD 2.37 billion by 2030, registering a CAGR of 6.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of the acromegaly disease is expected to drive the growth. For instance, the disease prevalence increased fourfold in 2015 from its previous year 2014, according to a report by the Endocrine Society. Moreover, growing investment in clinical trials by various pharmaceutical companies to develop new molecules is another factor propelling the market growth.

Furthermore, strong pipeline of drugs is anticipated to create growth opportunities in the forthcoming years. For instance, Mycapssa by Chiasma Inc. received approval in Europe in 2016. In 2018, Antisense Therapeutics launched their new formulation ALT1103 in U.S. ISIS 766720 by Ionis Pharmaceuticals Inc., a growth hormone receptor antagonist is currently under phase II clinical trial and is expected to be finished by December 2019.

The strong pipeline of drugs for somatostatin analogs is expected to propel growth of the acromegaly treatment market in near future. For instance, in 2018 around 30 clinical trials were being conducted in North America and many are waiting for the U.S. Food and Drug Administration (FDA) approval.

Acromegaly Treatment Market Report Highlights:

  • By drug class, the somatostatin analogues (SSAs) segment captured the largest market share of 65.0% in 2024, owing to their effectiveness in controlling growth hormone levels and managing symptoms.
  • On the besis of distribution channel, the hospital pharmacies segment garnered the largest share of 49.8% in 2024, attributed to their critical role in providing immediate and specialized care.
  • North America recorded the largest revenue share of 38.7% in 2024, due to the region's advanced healthcare infrastructure, high awareness levels, and access to cutting-edge treatments.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Acromegaly Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Acromegaly Treatment Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2030
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, By Drug Class, 2018 to 2030 (USD Million)
  • 4.4. Somatostatin Analogues (SSAs)
    • 4.4.1. Somatostatin Analogues (SSAs) Market, 2018 - 2030 (USD Million)
  • 4.5. Growth Hormone Receptor Antagonists (GHRAs)
    • 4.5.1. Growth Hormone Receptor Antagonists (GHRAs) Market, 2018 - 2030 (USD Million)
  • 4.6. Dopamine Agonists
    • 4.6.1. Dopamine Agonists Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Acromegaly Treatment Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2030
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, By Distribution Channel, 2018 to 2030 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Acromegaly Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamic
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamic
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamic
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamic
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamic
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamic
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamic
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamic
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamic
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Denmark Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Norway
      • 6.5.8.1. Key Country Dynamic
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Norway Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamic
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamic
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamic
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamic
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamic
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamic
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamic
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamic
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamic
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamic
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamic
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamic
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamic
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Acromegaly Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Novartis AG
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Ipsen Pharma
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Sun Pharmaceutical Industries Ltd
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Chiasma, Inc.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Peptron, Inc.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. WOCKHARDT
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Dauntless Pharmaceuticals
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Pfizer Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Ionis Pharmaceuticals, Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives